Exhale

The official blog of the Lung Institute.

New Data Suggests COPD Patients Will See Improvement from Stem Cell Therapy

10 Oct 2016
| Under Press | Posted by | 12 Comments
New Data Suggests COPD Patients Will See Improvement from Stem Cell Therapy

The Lung Institute’s updated COPD patient outcomes data suggests that 84.5 percent of patients see an improvement in their quality of life.

TAMPA, Fla. The Lung Institute released a new study showing positive results for the majority of patients with chronic obstructive pulmonary disease (COPD) who were treated with cell therapy, or therapy in which cellular material is injected into a patient. The Lung Institute utilizes stem cells and other cellular materials to treat patients with some chronic lung conditions. Jack Coleman, Jr., M.D., senior medical director of the Lung Institute, authored the study as a follow up to his original publication, Autologous Stem Cell Therapy and its Effects on COPD.

The most recent data includes 349 patients who were tested for quality of life improvement, and 53 patients who were tested for pulmonary function improvement. All patients were tested prior to treatment, and then three and six months post treatment.

Our physicians hope the results will help advance widespread acceptance of clinical application of cell therapy. “Many physicians don’t want to wait for perfection of a technology that may help a patient right now, in its early state, even though it may be better later. Our data shows that cell therapy is helping improve lives of those with chronic pulmonary conditions.”

Lung Institute white paper outcomes

The results indicate that, while not everyone will see improvement from cell therapy, most COPD patients will see improvement in their quality of life, 84.5 percent, to be exact. Quality of life is measured using the Clinical COPD Questionnaire (CCQ), which is recognized and accepted as a reliable quality of life measure by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as of 2013. Further, of those tested for pulmonary function, 49.1 percent saw an improvement of 10 percent or more, with the average improvement at 12 percent.

COPD is the most prevalent form of lung disease. “Just over 149,000 people die each year in the United States from chronic lung disease related problems,” said Dr. Coleman. According to the outcomes summary, COPD is expected to become the fourth leading cause of death worldwide by 2030. In fact, National Institutes of Health is currently developing a COPD National Action Plan, and is accepting public comment until Oct. 28.

“People have a desire and urgency to live,” said Dr. Coleman. “If there is something that I can do for a person to extend his or her life or, ideally, get them to a point that a cure is available, I will have performed consistently with my calling.”

Lung Institute white paper demographics

Until recently, treatment options for people with COPD have been limited. This is due to two reasons, according to the outcomes summary by our physicians. One is a lack of understanding of the physical progression of the disease itself on a molecular level, and two is a lack of a pharmaceutical development that addresses the disease on a primary pathophysiologic level. In other words, we have been treating the results of the pathophysiologic alterations caused by the disease process and not addressing the root causes of those pathphysiologic changes.

Treatment options today include supplemental oxygen, bronchodilators and corticosteroids, all of which address the symptoms rather than the disease itself. For those with more advanced cases of COPD, a lung transplant might be an option. However, there is currently a severe shortage of donor lungs, leaving many people to die on waiting lists prior to transplantation. For those who do undergo a transplant, the outcome is often bleak. Quality of life is generally decreased, and a transplant frequently comes hand in hand with a litany of health problems due to the need for lifelong immunosuppression. Immunosuppression is the suppression of a person’s immune response to a transplant organ, which is more commonly know as a rejection reaction. In other words, a person will likely be forced to take lifelong medications to prevent rejection of the organ. As a result, a lung transplant comes with a five year mortality rate of approximately 50 percent.

The FDA recently held hearings to discuss regulation of tissue-based therapies, and stem cell-related therapies were a major topic at the hearing. Most of those present at the hearing were in favor of clinical application of stem cell and other cell therapies, with patient after patient telling their unique  stories of how stem cells helped long standing, and often debilitating conditions, or even saved their lives. There were a few present who objected to clinical application of stem cell therapy today in favor of continuing research first. This would place control of who may and may not use cell therapies, and for what reason they may be used for patient care, into the hands of research scientists. It would also place clinical application on hold for several years. Many patients don’t have that much time.

White paper quality of life score

“I ask of them,” said Dr. Coleman, “to please not impede the abilities of those trying to take care of patients with what tools they have immediately at hand. I understand the desire to provide the best treatment possible, but it is the nature of the field of medicine that there are always better things on the horizon. We need to be able to treat our patients today, because too many of them will never live to see what is on the horizon. That is the simple, harsh reality of what we and our patients have to deal with day-to-day, and no amount of intellectual idealism will change that.”

To read a full copy of the new study by Dr. Coleman, visit https://lunginstitute.com/white-papers/stem-cell-therapy-and-its-effects-on-copd_september-2016-update/

About the Lung Institute

The Lung Institute is the leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. To date the organization has treated over 2,500 patients. The Lung Institute’s in-house outcomes summary shows that 84.5 percent of COPD patients studied saw an improvement in their quality of life. Founded in 2013 in Tampa, Fla., the Lung Institute currently operates clinics in Tampa, Fla., Nashville, Tenn., Scottsdale, Ariz., and Pittsburgh, Pa. and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 382-8095.

# # #

12 Comments

  1. PB

    2 months ago

    Dear Terry,

    Thanks for comment and question. At this time, we don’t have any data published in medical journals. However, we will pass your question along to our medical staff.

    Best Regards,

    The Lung Institute

  2. Terry Baird

    2 months ago

    Have you published any stem cell data in any medical Journals?

  3. PB

    2 months ago

    Dear George,

    Thanks for your questions. We are currently collecting outcomes data for pulmonary fibrosis. Once the data is collected and compiled, we’ll publish our findings, just like we have done for COPD. Keep checking in with us for updates. Also, you can hear the stories of patients with pulmonary fibrosis who have received treatment with us by clicking here. Once you are on the page, be sure to filter your results by clicking the “pulmonary fibrosis” button, and you’ll see testimonials from patients with PF. We’re happy to answer your questions about stem cell therapy, so feel free to contact us at (855) 313-1149. We look forward to hearing from you soon.

    Kind Regards,

    The Lung Institute

  4. PB

    2 months ago

    Dear Patricia,

    Yes, you can talk to patients that have had our treatments. To be put into contact with a patient who has had treatment, you need to first speak with a patient coordinator. Our patient coordinators can answer your questions about stem cell therapy, discuss treatment options and put you into contact with a patient who has had our treatment. So, contact us at (855) 313-1149, and we look forward to hearing from you soon.

    Best Regards,

    The Lung Institute

  5. PB

    2 months ago

    Dear Joe,

    Thanks for your comment and question. Many of our patients have used crowdsourcing and fundraising to raise funds for treatment. You can read more about this by clicking here. We’re happy to answer any questions you have about stem cell therapy, so feel free to contact us at (855) 313-1149. We look forward to hearing from you soon.

    Kind Regards,

    The Lung Institute

  6. George Gibson

    2 months ago

    I have noticed that most of your testimonials are from COPD patients. How much research has been done and found on pulmonary fibrosis? Do you have more testimonials from patients?

  7. Patricia jacobe

    2 months ago

    Can I talk to people that have has it done.

  8. Joe Harper

    2 months ago

    Is there any place that one can go to for financial help with stem cell therapy ? I would have the procedure done, but just don’t have the funds. Thanks in advance for any guidance.

  9. PB

    2 months ago

    Dear James,

    Thank you for your comment. We are currently collecting outcomes data on interstitial lung disease and pulmonary fibrosis. We will be publishing this data soon, so keep checking in with us.

    Best Regards,

    The Lung Institute

  10. James Beshear

    2 months ago

    Need a update on the results of stem cell success with pulmonary fibrosis

  11. PB

    2 months ago

    Dear Wildredo,

    Thanks for your question. We are currently collecting outcomes data on interstitial lung disease and pulmonary fibrosis, and we will be publishing this data soon. So, keep checking back with us.

    Kind Regards,

    The Lung Institute

  12. Wilfredo Vidal

    2 months ago

    Your comments are typically always geared to COPD, but not much on pulmonary fibrosis. Any updates on that?

Your Comment

Your email address will not be published.



* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.